Lactoferrin для Recurrent Infections

A Доказательства Несколько крупных клинических испытаний стабильно демонстрируют значительные преимущества.

Meta-analysis shows lactoferrin supplementation may reduce the odds of respiratory tract infections by 40-45%. A 90-day RCT demonstrated 58% reduction in respiratory infections versus placebo. Neonatal trial showed late-onset sepsis at 5.9% with lactoferrin versus 17.3% control.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'ingredient\u003Dlactoferrin\u0026condition\u003Drecurrent\u002Dinfections'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Итог

Key Study Findings

Case Reports n=1

Specific Granule Deficiency Due To Novel Homozygote SMARCD2 Variant.

Dose: None или: None Outcome: None Эффект: None None

Популяция: Patient with specific granule deficiency

Randomized Controlled Trial n=48 26.0 weeks Double-blind

Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, …

Dose: 500 mg или: Placebo Outcome: Disease remission Эффект: None None

Популяция: None

In Vitro

Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus.

Dose: None или: Conventional antibiotics Outcome: Killing efficacy against extra- and intracellular S. aureus Эффект: None None

Популяция: In vitro S. aureus cultures

Observational Study

Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study.

Dose: None или: Healthy controls Outcome: Antibacterial peptide levels in Crohn's disease Эффект: Decreased defensin and LL-37 in Crohn's patients None

Популяция: Crohn's disease patients

In Vitro

Unique human neutrophil populations are defined by monoclonal antibody ED12F8C10.

Dose: None или: None Outcome: immune function Эффект: None None

Популяция: animal model

Other n=14 52.0 weeks

Abnormal nasal glandular secretion in recurrent sinusitis.

Dose: 25 mg или: baseline Outcome: oxidative stress markers Эффект: or 2 None

Популяция: general population

Key Statistics

Исследования

2000

Участники

↑

Positive

Оценка

Referenced Papers

Specific Granule Deficiency Due To Novel Homozygote SMARCD2 Variant. Case Report

Pediatric allergy, immunology, … 2022 4 цитирований

Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. RCT

Beneficial microbes 2019 82 цитирований

Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus. Other

Antimicrobial agents and … 2013 115 цитирований

Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Other

Lancet (London, England) 2002 519 цитирований

Unique human neutrophil populations are defined by monoclonal antibody ED12F8C10. Other

Cellular immunology 1991 9 цитирований

Abnormal nasal glandular secretion in recurrent sinusitis. Other

The Journal of … 1990 50 цитирований

Studies of bronchial secretion. The influence of inflammatory response and bacterial infection. Other

Annals of allergy 1985 1 цитирований

Human neutrophil-specific granule deficiency: a model to assess the role of neutrophil-specific granules in the evolution of the inflammatory response. Other

Blood 1982

Lactoferrin deficiency as a consequence of a lack of specific granules in neutrophils from a patient with recurrent infections. Detection … Other

The American journal … 1980 138 цитирований

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Часто используемые дозировки

general:: 100-200 mg/day
immunesupport:: 200-600 mg/day

Верхний предел: No established UL; well-tolerated up to 1,200 mg/day

Дозировки, изученные в исследованиях

Дозировка	Длительность	Эффект	N
None	--	Mixed	1
500 mg	26.0 weeks	Positive	48
None	--	Positive	--
None	--	Negative	--
None	--	Neutral	--
25 mg	52.0 weeks	Mixed	14
None	--	Positive	60
None	468.0 weeks	Mixed	--

Лучшее время приёма: On empty stomach

Safety & Side Effects

Зарегистрированные побочные эффекты

⚠ Generally very well tolerated
⚠ Mild gastrointestinal effects at high doses
⚠ Allergic reactions in those with cow's milk allergy
⚠ Constipation (rare, due to iron-binding)

Известные взаимодействия

● May enhance absorption of certain antibiotics
● May interact with iron supplements (iron-binding properties)

Допустимый верхний уровень потребления: No established UL; well-tolerated up to 1,200 mg/day

Всегда консультируйтесь с врачом перед началом приёма любых добавок.Всегда консультируйтесь с лечащим врачом перед началом приёма любой добавки.

Frequently Asked Questions

Does Lactoferrin help with Recurrent Infections?

Based on 8 studies with 2,000 participants, there is strong evidence from multiple clinical trials that Lactoferrin may support Recurrent Infections management. Our evidence grade is A (Strong Evidence).

How much Lactoferrin should I take for Recurrent Infections?

Studies have used various dosages. A commonly studied range is 100-200 mg/day. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Lactoferrin?

Reported side effects may include Generally very well tolerated, Mild gastrointestinal effects at high doses, Allergic reactions in those with cow's milk allergy, Constipation (rare, due to iron-binding). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Lactoferrin and Recurrent Infections?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 8 peer-reviewed studies with 2,000 total participants. The overall direction of effect is positive.

Другие ингредиенты для Recurrent Infections

Bovine Colostrum B

Краткий вывод

Evidence Strength92%

High confidence

Разбор исследований

RCT (1)Meta (0)Other (7)

Сравнить альтернативы

Узнайте, как другие ингредиенты сравниваются при данном состоянии.

Посмотреть все ингредиенты для Recurrent Infections

Узнать больше

References

[1] Zeynep Kihtir et al.. Pediatr Allergy Immunol Pulmonol. 2022. Specific Granule Deficiency Due To Novel Homozygote SMARCD2 Variant. doi:10.1089/ped.2021.0070 PubMed
[2] R Russo et al.. Benef Microbes. 2019. Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. doi:10.3920/BM2018.0075 PubMed
[3] Jabeen Noore et al.. Antimicrob Agents Chemother. 2013. Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus. doi:10.1128/AAC.01650-12 PubMed
[4] Katrin Pütsep et al.. Lancet. 2002. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. doi:10.1016/S0140-6736(02)11201-3 PubMed
[5] C C Brown et al.. Cell Immunol. 1991. Unique human neutrophil populations are defined by monoclonal antibody ED12F8C10. doi:10.1016/0008-8749(91)90010-9 PubMed
[6] E V Jeney et al.. J Allergy Clin Immunol. 1990. Abnormal nasal glandular secretion in recurrent sinusitis. doi:10.1016/s0091-6749(05)80117-4 PubMed
[7] J Pryjma et al.. Ann Allergy. 1985. Studies of bronchial secretion. The influence of inflammatory response and bacterial infection. PubMed
[8] J I Gallin et al.. Blood. 1982. Human neutrophil-specific granule deficiency: a model to assess the role of neutrophil-specific granules in the evolution of the inflammatory response. PubMed
[9] J Breton-Gorius et al.. Am J Pathol. 1980. Lactoferrin deficiency as a consequence of a lack of specific granules in neutrophils from a patient with recurrent infections. Detection … PubMed

Отказ от ответственности FDA: Данные утверждения не были оценены Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов (FDA). Продукты и информация на этом сайте не предназначены для диагностики, лечения, излечения или профилактики каких-либо заболеваний. Представленные оценки доказательности основаны на нашем анализе опубликованных рецензируемых исследований и не являются медицинской консультацией. Всегда консультируйтесь с лечащим врачом перед началом приёма любых добавок.